Dosage evidence
BPC-157 Dosage: Why There Is No Established Dose
BPC-157's nomination was withdrawn, so it is not under consideration for the 503A bulks list. FDA's published concern is not that it is unsafe but that almost nothing is known.
Where BPC-157 stands with the FDA
“FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.”
There is no dose to report
There is no FDA-labeled dose and no human trial we could verify that establishes one. The mcg figures that circulate for BPC-157 are extrapolated from animal work, where doses are given per kilogram of body weight in rodents and do not translate directly to a human dose.
We would rather tell you this than publish a number. Pages that rank for “bpc-157 dosage” routinely state precise-looking figures with no citation attached to them. A number without a source is not more useful than an honest absence — it is less useful, because it looks like it came from somewhere.
Convert your prescribed dose to syringe units
If a clinician has prescribed BPC-157 for you, the number that matters next is how far to draw the syringe — and that depends on how much bacteriostatic water went into the vial, not on the peptide itself.
This converts a dose your prescriber has already given you into a volume and a number of units on a U-100 insulin syringe. It does not suggest a dose, and it does not tell you whether a peptide is appropriate for you. Most research peptides have no FDA-approved dosing, so there is no “standard” number for us to fill in. Doses here are in micrograms (mcg) — confusing mcg with mg is a 1,000-fold error and the single most common way people get this wrong.
Enter the dose your prescriber gave you, in micrograms, to see the volume and syringe units.
Your 5 mg vial in 2 mL of bacteriostatic water is —.
Keep reading
References
- 1.US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — category 2 of the interim policies, and the list of substances nominated but withdrawn. FDA Human Drug Compounding. 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
This page reports what regulators and published sources say about BPC-157. It is not medical advice, not a recommendation to use BPC-157, and not a dosing instruction. Every source above was opened and read on the date recorded in our data; regulatory status changes, so check the primary source before relying on it.